Compile Data Set for Download or QSAR
Report error Found 151 Enz. Inhib. hit(s) with all data for entry = 316
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM472(CHEMBL2110204 | 5-tert-butyl-4-{[(6S)-4-hydroxy-6-...)
Affinity DataKi:  0.0300nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM472(CHEMBL2110204 | 5-tert-butyl-4-{[(6S)-4-hydroxy-6-...)
Affinity DataKi:  0.0300nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409174(CHEMBL169119)
Affinity DataKi:  0.0300nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM430(PD 178390 Analog 23 | 3-[(2-tert-butyl-4-hydroxy-5...)
Affinity DataKi:  0.0300nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM465((6S)-3-[(4-amino-2-tert-butyl-5-methylphenyl)sulfa...)
Affinity DataKi:  0.0700nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM469(N-(5-tert-butyl-4-{[(6S)-4-hydroxy-2-oxo-6-(2-phen...)
Affinity DataKi:  0.200nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM469(N-(5-tert-butyl-4-{[(6S)-4-hydroxy-2-oxo-6-(2-phen...)
Affinity DataKi:  0.200nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM402(CHEMBL354027 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataKi:  0.210nM ΔG°:  -57.5kJ/molepH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM402(CHEMBL354027 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataKi:  0.210nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM470(N-(5-tert-butyl-4-{[(6S)-4-hydroxy-2-oxo-6-(2-phen...)
Affinity DataKi:  0.310nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM467(N-(5-tert-butyl-4-{[(6S)-4-hydroxy-6-[2-(4-hydroxy...)
Affinity DataKi:  0.390nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM467(N-(5-tert-butyl-4-{[(6S)-4-hydroxy-6-[2-(4-hydroxy...)
Affinity DataKi:  0.390nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM403(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataKi:  0.410nM ΔG°:  -55.7kJ/mole IC50: 2.20nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM403(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataKi:  0.410nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM398(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataKi:  0.530nM ΔG°:  -55.1kJ/mole IC50: 1.80nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM398(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataKi:  0.530nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM396(CHEMBL38268 | 3-[(4-amino-2-tert-butyl-5-methylphe...)
Affinity DataKi:  0.670nM ΔG°:  -54.5kJ/mole IC50: 2.70nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM396(CHEMBL38268 | 3-[(4-amino-2-tert-butyl-5-methylphe...)
Affinity DataKi:  0.670nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM464(CHEMBL354504 | 5-tert-butyl-4-{[(6R)-4-hydroxy-2-o...)
Affinity DataKi:  0.700nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM464(CHEMBL354504 | 5-tert-butyl-4-{[(6R)-4-hydroxy-2-o...)
Affinity DataKi:  0.700nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM421(CHEMBL169849 | N-(5-tert-butyl-4-{[4-hydroxy-2-oxo...)
Affinity DataKi:  0.830nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM421(CHEMBL169849 | N-(5-tert-butyl-4-{[4-hydroxy-2-oxo...)
Affinity DataKi:  0.830nM ΔG°:  -53.9kJ/molepH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM429(N-(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenyleth...)
Affinity DataKi:  1.04nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM448(CHEMBL171729 | 3-[(2-tert-butyl-4-hydroxy-5-methyl...)
Affinity DataKi:  1.10nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM448(CHEMBL171729 | 3-[(2-tert-butyl-4-hydroxy-5-methyl...)
Affinity DataKi:  1.10nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM452(CHEMBL168525 | 4-({6-[2-(4-aminophenyl)ethyl]-4-hy...)
Affinity DataIC50: 1.30nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM452(CHEMBL168525 | 4-({6-[2-(4-aminophenyl)ethyl]-4-hy...)
Affinity DataIC50: 1.30nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM423(N-(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenyleth...)
Affinity DataKi:  1.40nM ΔG°:  -52.6kJ/molepH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM423(N-(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenyleth...)
Affinity DataKi:  1.40nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM410(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.5nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM410(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.5nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM457(CHEMBL172271 | 3-({2-tert-butyl-4-[(ethylsulfamoyl...)
Affinity DataIC50: 1.70nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM457(CHEMBL172271 | 3-({2-tert-butyl-4-[(ethylsulfamoyl...)
Affinity DataIC50: 1.70nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM398(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.80nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409145(CHEMBL169878)
Affinity DataIC50: 1.90nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409134(CHEMBL171434)
Affinity DataIC50: 1.90nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM428(N-(5-tert-butyl-4-{[4-hydroxy-2-oxo-6-(2-phenyleth...)
Affinity DataIC50: 1.90nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM417(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 1.90nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM441(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 2nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409125(CHEMBL169256)
Affinity DataIC50: 2nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM414(CHEMBL168369 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataIC50: 2.10nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM414(CHEMBL168369 | N-[5-tert-butyl-4-({4-hydroxy-6-[2-...)
Affinity DataIC50: 2.10nMpH: 6.2 T: 2°CAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM454(4-({6-[2-(4-aminophenyl)ethyl]-4-hydroxy-2-oxo-6-(...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409170(CHEMBL86226)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM403(N-[5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxypheny...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM472(CHEMBL2110204 | 5-tert-butyl-4-{[(6S)-4-hydroxy-6-...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409138(CHEMBL171229)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM446(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetDimer of Gag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM431(5-tert-butyl-4-({4-hydroxy-6-[2-(4-hydroxyphenyl)e...)
Affinity DataIC50: 2.20nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Parke-Davis Pharmaceutical Research

LigandPNGBDBM50409127(CHEMBL170162)
Affinity DataIC50: 2.40nMAssay Description:Sensitivity of HIV-1 protease activity to protease inhibitors was determined by a peptide substrate cleavage assay. Protease products were analyzed o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/6/2004
Entry Details Article
PubMed
Displayed 1 to 50 (of 151 total ) | Next | Last >>
Jump to: